Information only. Not medical advice, and not a recommendation to use any compound. We do not sell or supply any compound Speak to a doctor before any decision about your health Information only. Not medical advice, and not a recommendation to use any compound. We do not sell or supply any compound Speak to a doctor before any decision about your health Information only. Not medical advice, and not a recommendation to use any compound. We do not sell or supply any compound Speak to a doctor before any decision about your health
Genexis Health
Melanocortin Scenesse

Melanotan I

Also known as Afamelanotide · NDP-MSH · developed by Clinuvel

Approved medicine

Licensed by at least one major regulator for a specific indication, on the strength of completed phase 3 trials. Approval is for that indication in that population — it is not a general endorsement of the compound.

Prescription medicine Licensed and available only on prescription in the UK, EU and US. Supply without a prescription is illegal.
Illustration only. Not a photograph of a product, and not an offer of supply — Genexis Health does not sell or supply Melanotan I.

What it is

A linear, MC1R-selective analogue of alpha-MSH. Unlike Melanotan II it completed clinical development and is a licensed medicine — though for a rare condition, not for cosmetic tanning.

How it is thought to work

Selective MC1R agonist, stimulating eumelanin production. Selectivity is the key difference from Melanotan II: it largely avoids the MC3R and MC4R effects.

What the studies found

  • Approved for erythropoietic protoporphyria

    Randomised trials showed increased pain-free sunlight exposure in people with EPP, a rare inherited disorder causing severe phototoxic pain. Approved in the EU in 2014 and by the FDA in 2019, administered as a subcutaneous implant under specialist supervision.

What the evidence does not show

  • The evidence base is for EPP specifically. It says little about use by people without the condition.
  • It is supplied as a controlled-release implant placed by a clinician, not as an injectable.
  • Long-term pigmentary and melanoma surveillance data remains limited.

Reported risks and adverse effects

  • Reported effects include nausea, headache and localised skin reactions.
  • Regular skin monitoring is part of the licensed protocol, because increased pigmentation can obscure skin lesions.
  • The safety profile that supported approval reflects specialist administration and monitoring.

This is a summary of what has been reported in the literature, not a complete safety profile. For anything concerning your own health, speak to a doctor.

Regulatory status

A licensed prescription medicine for EPP in the EU and US, supplied as an implant through specialist centres. It is not licensed for cosmetic use anywhere.

Where it acts

The sites below are where Melanotan I is understood to act, paired with what was actually measured there and in whom. A site on this diagram means a compound acts there — not that a benefit is established.

Drag to turn · tap an organ

1
Stylised illustration. Marker positions are indicative, not anatomically precise.
  1. Selective MC1R agonist on melanocytes, stimulating eumelanin production.

    What was measuredApproved for erythropoietic protoporphyria: increased pain-free sunlight exposure in a small, rare-disease population. This is the only indication it is licensed for.